Document is current
Any future updates will be listed below
-
Authors
Wu, Yu https://orcid.org/0000-0002-7510-1223
Pan, Yuesong https://orcid.org/0000-0003-3082-6789
Wang, Mengxing https://orcid.org/0000-0002-4245-4014
Meng, Xia
Wang, Yilong
Li, Shuya https://orcid.org/0000-0002-7263-0365
Wang, Yongjun https://orcid.org/0000-0002-9976-2341
Zhou, Yilun
Du, Wanliang
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04797013 at ClinicalTrials.govnct04797013 at ClinicalTrials.govDocuments that mention this clinical trial
Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design
https://doi.org/10.1136/svn-2021-001074
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
https://doi.org/10.1136/svn-2023-002310
Influence of impaired renal function on the outcomes of patients with acute ischaemic stroke treated with intravenous tenecteplase and alteplase: a post hoc analysis of the TRACE-2 trial
https://doi.org/10.1136/svn-2024-003726
Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial
https://doi.org/10.1136/svn-2023-002694
Documents that mention this clinical trial
Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design
https://doi.org/10.1136/svn-2021-001074
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
https://doi.org/10.1136/svn-2023-002310
Influence of impaired renal function on the outcomes of patients with acute ischaemic stroke treated with intravenous tenecteplase and alteplase: a post hoc analysis of the TRACE-2 trial
https://doi.org/10.1136/svn-2024-003726
Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial
https://doi.org/10.1136/svn-2023-002694
-
Funding
Funding for this research was provided by:
Key R&D Program of China (2017YFC1308204)
Beijing Municipal Administration of Hospitals Incubating Program (PX2018022)
National Natural Science Foundation of China (81870905)
Guangzhou Recomgen Biotech Co., Ltd
National Science and Technology Major Project (2017ZX09304018)
- License Information
